Comparison of each of the patient-reported outcomes and physiological measurement during the recovery phase from acute exacerbation of COPD
Patient-reported outcomes | Day 1 | Day 7 | Day 14 | Day 21 | Day 28 | Day 56 | Day 84 | |||||||
n | n | n | n | n | n | n | ||||||||
Patient-reported outcomes | ||||||||||||||
EXACT total score | 33 | 50.5±12.4 | 32 | 37.0±11.6 | 31 | 32.5±14.3 | 32 | 35.0±16.2 | 33 | 33.4±14.9 | 30 | 33.1±14.6 | 27 | 33.4±16.0 |
Breathlessness domain score | 33 | 54.7±24.9 | 33 | 34.4±19.4 | 32 | 28.3±25.4 | 32 | 36.1±26.0 | 33 | 33.0±25.0 | 30 | 32.9±23.8 | 27 | 35.6±26.4 |
Cough and sputum domain score | 33 | 38.8±21.8 | 33 | 26.1±13.9 | 32 | 17.2±13.7 | 32 | 19.5±14.6 | 33 | 19.0±19.2 | 30 | 18.4±16.5 | 27 | 19.0±15.7 |
Chest symptoms domain score | 33 | 48.0±20.0 | 33 | 27.5±17.2 | 32 | 19.4±18.8 | 32 | 26.7±20.7 | 33 | 21.6±21.0 | 30 | 19.8±20.4 | 27 | 22.3±21.3 |
CAT score | 33 | 24.4±8.5 | 33 | 16.2±7.3 | 32 | 13.5±8.4 | 32 | 13.9±8.1 | 33 | 13.3±8.4 | 30 | 13.7±8.3 | 27 | 13.3±8.6 |
SGRQ total score | 31 | 55.1±19.8 | 33 | 49.3±22.4 | 32 | 41.8±25.3 | 31 | 44.3±23.9 | 32 | 42.1±23.3 | 29 | 40.3±23.6 | 26 | 40.6±25.5 |
SGRQ symptoms | 31 | 66.7±20.8 | 33 | 68.9±17.4 | 32 | 63.2±20.7 | 32 | 63.5±21.4 | 32 | 61.8±23.6 | 30 | 56.7±20.1 | 27 | 52.4±25.5 |
SGRQ activity | 31 | 67.7±25.9 | 33 | 58.7±28.7 | 32 | 51.2±32.5 | 31 | 56.5±31.0 | 32 | 54.2±30.9 | 29 | 51.7±30.9 | 26 | 54.8±33.2 |
SGRQ impact | 31 | 44.2±22.2 | 33 | 37.9±24.2 | 32 | 29.9±26.4 | 32 | 30.0±24.6 | 33 | 28.0±22.6 | 30 | 29.7±23.3 | 27 | 27.3±25.2 |
Hyland Scale score | 31 | 42.6±20.7 | 32 | 59.7±21.2 | 32 | 63.8±21.0 | 30 | 61.5±21.1 | 31 | 61.0±21.6 | 27 | 59.8±17.6 | 26 | 61.3±20.8 |
D-12 total score | 30 | 10.3±9.7 | 30 | 5.3±5.5 | 32 | 3.8±5.3 | 31 | 4.6±6.0 | 32 | 4.3±5.7 | 30 | 3.4±6.0 | 26 | 3.8±6.4 |
D-12 physical score | 30 | 7.3±5.9 | 32 | 4.3±3.8 | 32 | 2.8±3.6 | 31 | 3.4±4.0 | 32 | 3.1±3.7 | 30 | 2.4±3.6 | 26 | 2.8±4.1 |
D-12 affective score | 31 | 3.2±4.1 | 31 | 1.2±2.2 | 32 | 1.0±1.9 | 31 | 1.3±2.4 | 32 | 1.1±2.2 | 30 | 1.0±2.6 | 27 | 1.0±2.4 |
Spirometry | ||||||||||||||
FVC (L) | 31 | 2.17±0.68 | - | - | 33 | 2.45±0.61 | - | - | 33 | 2.45±0.64 | 32 | 2.46±0.65 | 30 | 2.46±0.67 |
FVC (%predicted) | 31 | 71.6±22.8 | - | - | 33 | 81.0±20.1 | - | - | 33 | 81.6±22.7 | 32 | 83.0±23.4 | 30 | 81.0±22.3 |
FEV1 (L) | 31 | 1.02±0.50 | - | - | 33 | 1.22±0.53 | - | - | 33 | 1.20±0.53 | 32 | 1.19±0.55 | 30 | 1.22±0.56 |
FEV1 (%predicted) | 31 | 42.7±19.1 | - | - | 33 | 51.6±20.7 | - | - | 33 | 51.3±22.2 | 32 | 51.6±23.8 | 30 | 51.3±22.9 |
Arterial blood gas* | ||||||||||||||
PaO2 (mm Hg) | 32 | 67.5±11.4 | - | - | 33 | 75.6±12.3 | - | - | 33 | 76.7±14.4 | 33 | 75.9±11.1 | 30 | 73.4±13.4 |
PaCO2 (mm Hg) | 32 | 42.0±12.1 | - | - | 33 | 43.1±8.2 | - | - | 33 | 42.7±7.9 | 33 | 42.2±7.8 | 30 | 43.7±8.0 |
pH | 32 | 7.408±0.048 | - | - | 33 | 7.397±0.030 | - | - | 33 | 7.395±0.032 | 33 | 7.401±0.031 | 30 | 7.388±0.030 |
*Oxygen was administered to six subjects; one subject received non-invasive positive pressure ventilation. Data are presented as mean±SD.
CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; D-12, Dyspnoea-12; EXACT, Exacerbations of Chronic Pulmonary Disease Tool; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PaCO2, arterial carbon dioxide pressure; PaO2, arterial oxygen pressure; SGRQ, St George’s Respiratory Questionnaire.